A variant of advanced disease known as treatment-emergent small-cell neuroendocrine prostate cancer is fairly common after use of abiraterone and/or enzalutamide.
Medscape Medical News
Original Article: Aggressive Prostate Cancer Type Is 'Fairly Prevalent'